DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time

We report on the immunogenicity and clinical effects in a phase I/II dose escalation trial of a DNA fusion vaccine in patients with prostate cancer. The vaccine encodes a domain (DOM) from fragment C of tetanus toxin linked to an HLA-A2-binding epitope from prostate-specific membrane antigen (PSMA),...

Descripción completa

Detalles Bibliográficos
Autores principales: Chudley, Lindsey, McCann, Katy, Mander, Ann, Tjelle, Torunn, Campos-Perez, Juan, Godeseth, Rosemary, Creak, Antonia, Dobbyn, James, Johnson, Bernadette, Bass, Paul, Heath, Catherine, Kerr, Paul, Mathiesen, Iacob, Dearnaley, David, Stevenson, Freda, Ottensmeier, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493666/
https://www.ncbi.nlm.nih.gov/pubmed/22729556
http://dx.doi.org/10.1007/s00262-012-1270-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493666/
https://www.ncbi.nlm.nih.gov/pubmed/22729556
http://dx.doi.org/10.1007/s00262-012-1270-0

Ejemplares similares